Immuno-Oncology | Specialty

Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

August 9th 2023

The PD-1 inhibitor pembrolizumab displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes.

Pembrolizumab Generates Sustained Responses in Relapsed/Refractory PMBCL

August 5th 2023

Pembrolizumab produced sustained antitumor activity in patients with relapsed/refractory primary mediastinal large B-cell lymphoma, according to data from the final analysis of the phase 2 KEYNOTE-170 trial.

Investigators Pursue the Role of the Microbiome on Immunotherapy Treatment in RCC

August 1st 2023

Pedro C. Barata, MD, MSc, discusses the importance of further exploring the facets of manipulating the microbiome to augment responses with immunotherapy in RCC, as well as the promise of the bifidogenic live bacterial product, CBM588.

ASCO Presentations Indicate Bright Future For Immunotherapy Combinations in Soft Tissue Sarcoma

July 31st 2023

Jonathan C. Trent, MD, PhD, discusses data from 2 phase 2 trials of immunotherapy in soft tissue sarcoma, as well as their clinical significance.

PD-1 Inhibitors Demonstrate Promise as Salvage Therapy in R/R Extranodal NK/T-cell Lymphoma

July 31st 2023

Amira Marouf, MD, PhD student, describes the nature of a comparative analysis conducted based on propensity score matching, and discussed the main takeaways regarding the efficacy of PD-1 inhibitors for patients with relapsed/refractory ENKTCL.

Neoadjuvant Pembrolizumab Plus Chemotherapy Improves pCR Rate in High-Risk, Early-Stage ER+/HER2– Breast Cancer

July 28th 2023

Neoadjuvant pembrolizumab plus chemotherapy led to an improvement in pathological complete response rate compared with chemotherapy plus placebo in patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.

Long-Term Data Show Improved CR Rates for Cosibelimab in Advanced CSCC

July 28th 2023

Long-term data demonstrated that treatment with cosibelimab improved complete response rates over time in patients with locally advanced or metastatic cutaneous squamous cell carcinoma in a phase 1 trial.

mRNA-4157 Plus Pembrolizumab Under Further Investigation in Phase 3 Trial in High-Risk Melanoma

July 26th 2023

The combination of mRNA-4157 and pembrolizumab will be further evaluated as an adjuvant treatment option for patients with resected, high-risk, stage IIB to IV melanoma in the phase 3 V940-001 trial.

First-Line Rivoceranib Plus Camrelizumab Improves Survival in Unresectable HCC

July 25th 2023

Treatment with the combination of rivoceranib and camrelizumab led to a statistically significant and clinically meaningful benefit in progression-free survival and overall survival compared with sorafenib in previously untreated patients with unresectable hepatocellular carcinoma.

Evaluating Toxicities of Antineoplastic Drug Therapeutics: Is It Time for a Critical Review?

July 24th 2023

An evaluation of the utility of a cancer therapeutic in a clinical trial is determined through metrics that define 2 distinctive features of an antineoplastic strategy: efficacy and toxicity. Although that may be an oversimplification, the aim of such therapy is to improve clinical outcomes.

Fianlimab Plus Cemiplimab Produces Durable Responses in Advanced Melanoma

July 24th 2023

Omid Hamid, MD, discusses the key efficacy and safety findings for the combination of fianlimab plus cemiplimab in patients with advanced melanoma.

CHMP Supports Approval of Pembrolizumab Plus Trastuzumab/Chemotherapy for HER2+, PD-L1+ Advanced Gastric/GEJ Cancer

July 21st 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of pembrolizumab plus trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of patients with advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors have a PD-L1 combined positive score of at least 1.

ENB-003 Plus Pembrolizumab Elicits Safety, Activity in Ovarian Cancer and Other Advanced, Refractory Solid Tumors

July 20th 2023

Treatment with the combination of ENB-003 and pembrolizumab was well tolerated and produced preliminary signs of clinical activity in patients with platinum-refractory or -resistant, microsatellite stable ovarian cancer, and those with other advanced refractory solid tumors.

Tislelizumab Plus Bevacizumab/Chemo Demonstrates Early Efficacy in Cervical Cancer

July 20th 2023

The addition of the PD-L1 inhibitor tislelizumab to standard bevacizumab and platinum-doublet chemotherapy in the first-line setting prolonged progression-free survival, produced encouraging responses, and was well tolerated in patients with cervical cancer.

Pembrolizumab Plus Chemoradiotherapy Meets PFS End Point in High-Risk Locally Advanced Cervical Cancer

July 19th 2023

The addition of pembrolizumab to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, improved progression-free survival vs concurrent chemoradiotherapy alone in newly diagnosed patients with high-risk locally advanced cervical cancer.

Setanaxib Plus Pembrolizumab Elicits PFS Benefit in Recurrent or Metastatic HNSCC

July 18th 2023

The combination of the NOX1/4 inhibitor setanaxib and pembrolizumab produced progression-free survival benefits compared with placebo plus pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Immuno-Oncology Approaches Continue to Advance Across Gynecologic Cancers

July 11th 2023

Michael J. Birrer, MD, PhD, highlights the effect of improved molecular characterization in endometrial cancer, the clinical significance of the KEYNOTE-775 trial, and recent changes in the frontline treatment landscape in advanced endometrial cancer.

ONC-392/BNT316 Elicits Clinical Activity in Checkpoint Inhibitor–Resistant NSCLC

July 2nd 2023

ONC-392/BNT316 demonstrated early signs of antitumor activity and manageable safety in patients with metastatic, PD-(L)1–resistant non–small cell lung cancer.

Adjuvant Pembrolizumab Continues to Provide Survival Benefit in Stage IIB/C Melanoma

June 30th 2023

Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis–free survival vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma

Neoadjuvant Nivolumab/Chemo Wins EU Approval for Resectable PD-L1+ NSCLC

June 29th 2023

The European Commission has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of patients with resectable non–small cell lung cancer at high risk of recurrence with tumor cell PD-L1 expression of at least 1%.